Clinical Trials Browser

Phase 1 × Breast Neoplasms × Alpelisib × Clear all

Breast Neoplasms, Neoplasm Metastasis

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03207529 2024-10-10

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Phase 1 Completed

18 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01791478 2024-07-23

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Phase 1 Active not recruiting

46 enrolled

Breast

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT01300962 2023-12-04

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Phase 1 Completed

47 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02167854 2021-07-09

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Phase 1 Completed

23 enrolled

Breast

Breast Neoplasms

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

118 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT02088684 2020-12-17

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1 Completed

70 enrolled

Breast

Breast Neoplasms

NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Phase 1 Completed

62 enrolled

Breast

Acrocephalosyndactylia, Breast Neoplasms

NCT02051751 2020-12-08

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Phase 1 Completed

19 enrolled

BreastHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT02077933 2020-12-08

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Phase 1 Completed

79 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT02038010 2020-06-29

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Phase 1 Completed

17 enrolled 17 charts

Breast

Breast Neoplasms

Clinical Trials

ASSET

EMBER

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer

Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx